Viral Load Guided Immunosuppression After Lung Transplantation

  • End date
    Dec 1, 2025
  • participants needed
  • sponsor
    Philipps University Marburg Medical Center
Updated on 3 June 2021


The VIGILung study is an open-label, randomized, multicenter trial in lung transplant recipients to investigate the safety and efficacy of personalized immunosuppression guided by DNA monitoring of Torque-Teno-Virus (TTV). The aim of the study is to investigate an individual adaptation of the calcineurin inhibitor tacrolimus (tailored calcineurin inhibitor dosing) by a non-invasive biomarker (TTV viral load in whole blood) compared to conventional calcineurin inhibitor dosing. Indicator for toxicity will be the glomerular filtration rate (GFR), which will be estimated using the CKD-EPI formula. 250 patients (age 18 years) with 21 to 42 days after de novo lung transplantation (bilateral or combined) will be screened as possible subjects eligible for the study. N = 144 patients have to be randomized in two study arms. In Arm 1 tacrolimus doses will be adapted according to the tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load. In Arm 2 tacrolimus doses will be adapted according to TDM.

Condition Lung transplant
Treatment Tailored tacrolimus dosing, Conventional tacrolimus dosing
Clinical Study IdentifierNCT04198506
SponsorPhilipps University Marburg Medical Center
Last Modified on3 June 2021


Yes No Not Sure

Inclusion Criteria

patients 21 to 42 days after primary de novo lung transplantation (bilateral including combined)
age 18 years
tacrolimus based immunosuppression
written informed consent
detectable TTV load at randomization (>2,7 log 10)
negative serum pregnancy test in women of childbearing potential
women of childbearing capacity must agree to maintain highly effective methods of contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of the study. If abstinence is not practiced, a combination of hormonal contraceptive (oral, injectable or implants) and a barrier method (condom, diaphragm with a vaginal spermicidal agent) has to be used

Exclusion Criteria

patients after unilateral or re-do lung transplantation
history or high-risk of obstructive airway complications after lung transplantation
respiratory failure (need for oxygen therapy or ventilation at screening after lung transplantation)
inability to undergo transbronchial biopsy
advanced kidney failure (GFR CKD-EPI <30 ml/min/1.73m2 at inclusion and/or current renal replacement therapy at inclusion or randomization
advanced liver cirrhosis (CHILD-Pugh Score C) after lung transplantation
fluctuating tacrolimus drug levels (less than 20% in target range after transplantation)
symptoms of significant mental illness and with inability to cooperate or communicate with the investigator
unlikeliness to comply with the study requirements
HIV positivity
evidence of unsolved drug or alcohol addiction
breastfeeding women
simultaneous participation in other clinical trials if not permitted by the steering committee
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note